Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome

Individuals with Down syndrome (DS) often present with inflammatory skin diseases such as atopic dermatitis (AD) and alopecia areata (AA). They represent a vulnerable population that is seldom included in clinical trials. We propose a clinical trial to evaluate the long-term safety, efficacy, and mechanisms of two novel JAK1 (abrocitinib) and JAK3/TEC (ritlecitinib) inhibitors, recently FDA-approved for AD and AA respectively, in patients with DS, so that individuals with DS can be appropriately treated.